Regarding epilepsy, there were 3 eligible studies included (EPO group/control group = 310/303), and significant heterogeneity was detected among these trials (χ2 = 4.46, P = 0.11; I2 = 55.2%). The gene discussed is EPO; the disease is epilepsy.